{"id":"W2994089043","doi":"10.1182/blood-2019-123064","title":"Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Anemia; Placebo; Internal medicine; Erythropoiesis; International Prognostic Scoring System; Randomized controlled trial; Clinical trial; Erythropoietin; Myelodysplastic syndromes; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002360149,0.001826234,0.002119247,0.0003265684,0.0004254743,0.001237829,0.0008867672,0.001830021,0.009492144],"category_scores_gemma":[0.001620918,0.0005860925,0.002000436,0.0003188562,0.001153535,0.001269213,0.0003768512,0.00378864,0.001709096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007372104,"about_ca_system_score_gemma":0.0009549041,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003581079,"about_ca_topic_score_gemma":0.001189474,"domain_scores_codex":[0.9993993,0.0002901207,0.0000446722,0.000119677,0.00005334094,0.00009288394],"domain_scores_gemma":[0.9989255,0.0002095768,0.0003944272,0.00008136042,0.00009300606,0.000296159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.968452,0.008874673,0.0006131764,0.0009423614,0.001187059,0.00004277582,0.00005296964,0.0003438716,0.004340987,0.0001427443,0.001747424,0.01326004],"study_design_scores_gemma":[0.9067909,0.08809595,0.002131099,0.0000428761,0.0006027995,0.00005762296,0.00001967213,0.0003754616,0.0006457095,0.0002124802,0.001006639,0.00001889931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737171,0.007717886,0.001195152,0.001376705,0.0008821603,0.006513212,0.003184826,0.0002877732,0.005125103],"genre_scores_gemma":[0.9817976,0.002200336,0.001394621,0.001737261,0.0005639825,0.005805189,0.001908987,0.00003076068,0.004561334],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009492144,"threshold_uncertainty_score":0.03175431,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01288430339612391,"score_gpt":0.2856738940147149,"score_spread":0.272789590618591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}